The American Academy of Dermatology’s Annual Meeting is “the premier dermatology education event of the year” (AAD.org). This year, we’re sharing the conference headlines from Dermatology Daily, the official daily news briefing for AAD members that we produce in partnership with AAD, to bring our readers up to speed on 2025 AAD.
This year’s meeting included numerous research and therapeutic breakthroughs, with emphasis on inflammatory, autoimmune, and precancerous skin diseases, as well as major leadership changes at AAD. Read on for the top highlights covered in Dermatology Daily!
Association News
New AAD President Says She Will Focus On “Taking Care Of Dermatologists”: Healio
Research News
Actinic Keratosis
Bimiralisib Demonstrates Potential In Treating Patients With Actinic Keratosis, Analysis Shows: HCPlive
Tirbanibulin Reduces Actinic Keratosis Lesions, Achieves High Patient Satisfaction, Data Show: HCPlive
Alopecia
Ritlecitinib Efficacious Against Alopecia Areata And Supported For Long-Term Use In Patients 12 And Older, Study Finds: Dermatology Advisor
Oral Baricitinib Effective In Treating Adolescents With Severe Alopecia Areata, Study Shows: Healio
Atopic Dermatitis
Lebrikizumab Can Effectively Treat Atopic Dermatitis For Up To Three Years, Data Show: HCPlive
AD Disease Activity Remained Mild After Patients Treated With Tapinarof Achieved Nearly 80 Consecutive Treatment-Free Days, Study Finds: Healio
Delgocitinib Cream Shows Promise In Treating Patients With Moderate To Severe Chronic Hand Eczema, Data Show: HCPlive
Patients With AD Treated With JAK Inhibitors Had Increased Infection Risk Compared To Those Who Received Th2 Cytokine Inhibitors, Study Says: Dermatology Advisor
Rocatinlimab Leads To At Least 75% Improvement In A Third Of Patients With Atopic Dermatitis After 6 Months, Trial Finds: MedPage Today
Hidradenitis Suppurativa
Bimekizumab-Bkzx Effective In Promoting Sustained Control Of Moderate-To-Severe Hidradenitis Suppurativa, Study Finds: HCPlive
Patients With HS Have Increased Risk Of Developing Various Inflammatory Arthropathies, Research Suggests: Dermatology Advisor
Lichen Planus
Clinicians Consistently Use Topical Corticosteroids, Topical Calcineurin Inhibitors, Intralesional Corticosteroids, And Oral Immunosuppressants For Treatment Of LP, Findings Show: Dermatology Advisor
Psoriasis
Icotrokinra Helped Nearly 50% Of Patients With Moderate To Severe Plaque Psoriasis At 24 Weeks, Trial Results Suggest: HCPlive
Studies Highlight Efficacy, QOL Improvements Of Tildrakizumab For Patients With Moderate To Severe Psoriasis: The American Journal of Managed Care
Guselkumab Associated With Substantial Clinical Improvement In Patients With Fingernail Psoriasis, Study Says: Dermatology Advisor
Psoriatic Arthritis
Deucravacitinib Effective At Improving Symptoms, Quality Of Life In Patients With PsA, Study Finds: HCPlive
Deucravacitinib Shows Potential In Treating PsA, CLE In Separate Studies: MedPage Today
Rare Skin Disorders
Dupilumab Use Associated With Significant Improvements In Disease Activity, Burden Among Patients With Bullous Pemphigoid, Data Suggest: HCPlive
Use Of Ruxolitinib Cream 1.5% Associated With Significant Improvement In Itch Seven Days After Starting Therapy Among Adults With PN, Data Show: HCPlive
For more industry insights like this, follow us on LinkedIn and Instagram!
